Voluntary Scheme for Branded Medicines Pricing and Access
Eli Lilly and InnoCare Pharma agree on $3.3bn drug research deal
The deal focuses on addressing critical unmet medical needs
Lilly to acquire Merida Biosciences in deal worth up to $2.875bn
The acquisition is to advance treatments for serious autoimmune and allergic diseases
Eli Lilly’s Foundayo authorised by UK MHRA for weight loss and type 2 diabetes
The UK is the first country in Europe to authorise the oral medication
Lilly’s olomorasib gets FDA Breakthrough Therapy designation for pancreatic cancer
Around 60,000 people in the US get pancreatic cancer each year, with an estimated 50,000 deaths projected annually
AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo
Rinvoq is the first and only systemic medication approved in the EU for NSV
Lilly to acquire AtaiBeckley in deal worth $2.8bn
The acquisition will advance therapies for treatment-resistant depression and other mental health conditions
AbbVie to acquire Apogee Therapeutics in $10.9bn deal
The acquisition includes clinical-stage candidates for atopic dermatitis and asthma
Lilly’s Ebglyss approved by FDA as maintenance dose for atopic dermatitis
This new option for patients allows for as few as six maintenance injections per year
Lilly to acquire LimmaTech Biologics and Vaccine Company in deals totalling $2.33bn
The acquisitions reinforce the company’s commitment to reduce the long-term burden of serious disease
Lilly and UNICEF collaborate to improve non-communicable disease prevention
Six-year initiative to improve NCD prevention and care for children in low- and middle-income countries
Lilly commits additional $4.5bn for US manufacturing sites
The company has also opened its first dedicated genetic medicine facility in Indiana in the US
Eli Lilly to acquire Kelonia Therapeutics in deal worth up to $7bn
The acquisition will help Lilly to expand its capabilities in cell and gene therapy